UBS sets USD 104.00 target for Cytokinetics stock

Published on 10/17/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value was USD 8.6 billion on October 16, 2026. Cytokinetics stock stood at EUR 55.12 that date, down 3.08 percent on Nasdaq.

Analyst target and reporting date

UBS analyst Ashwani Verma set a USD 104.00 target on October 14, 2026.
Cytokinetics had USD 8.6 billion in market value on October 16, 2026.
Cytokinetics stock stood at EUR 55.12 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST, down 3.08 percent on Nasdaq.
MarketBeat lists November 4, 2026 as the estimated third-quarter reporting date.

CYTK, US23282W6057, Illustration mit AI erstellt.

Cytokinetics (ISIN US23282W6057) had a USD 104.00 analyst target from UBS on October 14, 2026, which stood 67.88 percent above the Nasdaq quote of USD 61.95. UBS analyst Ashwani Verma reiterated a Buy rating and set the target, as Markets Insider reported. At Lang & Schwarz, Cytokinetics stock stood at EUR 55.12 on October 16, 2026 at 10:58 p.m. CEST; the Nasdaq quote fell 3.08 percent to USD 61.95 from USD 63.92.

Target distance and market value

The UBS target gives investors a clear valuation reference in the company currency, while the market capitalization was USD 8.6 billion on October 16, 2026. Cytokinetics has no dividend yield, and its price-to-earnings ratio was minus 8.58 on the same date. The negative ratio reflects the company's loss-making earnings base rather than a conventional earnings multiple.

Range and trading volume

The Nasdaq quote stood 14.09 percent above the 52-week low of USD 54.30 and 29.85 percent below the 52-week high of USD 88.31 on October 16, 2026. Trading volume was 1,204,435 shares against an average volume of 1,967,746 shares. On August 6, 2026, Cytokinetics reported its second-quarter results, with the period covered by Zacks.

Valuation and reporting date

MarketBeat lists November 4, 2026 as the estimated date for Cytokinetics' third-quarter results, with the conference call scheduled for 4:30 p.m. ET. That date gives the next defined calendar point for the stock after the October research updates.

Comparison with peers

Cytokinetics (Nasdaq, USD): minus 3.08 percent, P/E minus 8.58, market capitalization USD 8.6 billion

Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E minus 5.90, market capitalization USD 1.8 billion

Alnylam Pharmaceuticals (Nasdaq, USD): minus 0.94 percent, P/E 39.16, market capitalization USD 31.0 billion

Nasdaq move and euro quote

The stock's 52-week position leaves it above its recent low but below its yearly high, while the negative price-to-earnings ratio keeps earnings the central valuation constraint. The last available euro indication stood at EUR 55.12 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST, while the Nasdaq quote was down 3.08 percent against its prior close. The further course of trading is shown by the continuously updated real-time quote of Cytokinetics stock.